Gregory A. Abel, MD, MPH
Director, Older Adult Hematologic Malignancy Program
Assistant Professor of Medicine, Harvard Medical School
Office phone: 617-632-1906
Preferred contact method: office phone
View Physician Profile
Leukemia, Myelodysplastic syndromes, Myeloproliferative disorders
Area of Research
Health Services Research, Outcomes Research, Hematologic Malignancies
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Other Practice Locations
Brigham and Women's Hospital
221 Longwood Ave.
Boston, MA 02115
BiographyDr. Abel received his MD and MPH from Columbia University in 2000. He completed his postgraduate training in internal medicine at Massachusetts General Hospital and his hematology/oncology fellowship at Dana-Farber Cancer Institute. In 2007, he joined Dana-Farber and is a member of the Hematologic Malignancies staff, as well as the Center for Outcomes and Policy Research.
ResearchHealth Services Research, Outcomes Research, Hematologic Malignancies
My research aims to apply health services methods to understand the experiences of patients with cancer and to answer questions about the effectiveness of cancer care. I am also interested in evaluating how intensive cancer therapy affects outcomes other than survival, such as quality of life and financial well-being. I primarily focus on the hematologic malignancies, studying the impact of these diseases and their treatment from diagnosis to the end of life. Specific interests have included the impact of direct-to-consumer advertising in cancer care, utility of surveillance imaging for patients with diffuse large B-cell lymphoma, effects of delays in diagnosis for blood cancers, and therapeutic changes and treatment disparities for patients with multiple myeloma. I have also been fortunate to receive a grant from the Leukemia and Lymphoma Society for a longitudinal study to compare the effectiveness of treatments for older patients with myelodysplastic syndromes (MDS). Another project aims to characterize the financial burden experienced by patients who undergo stem cell transplantation, and whether an increase in that burden is associated with compromised outcomes. Finally, I am interested in expanding and improving the tools available for outcomes research in hematologic oncology. For example, I am developing a new disease-specific measure of quality of life for patients with MDS (the “QUALMS-1”), and have created an MDS prognostic scoring system for use with the large SEER-Medicare dataset.